My research focus on clustered signaling pathways of molecular partners in defined subcellular compartments (signalosomes) that enables cells to exert highly specialized tasks. Actually, our goal for the future is to unravel the organization of the recently discovered signaling components within functional units by biochemical, molecular, cell biological methods, genetic and omic’s. Research is embedded in the field of integrative pharmacology and translational medicine. We have directed our attention to chronic inflammatory disorders, as evidence exist for a role of our signaling components (Epac, PLD, AKAP, cofilin) in smooth muscle cells, neuronal cells, immune cells as well as cardiomyocytes. Many devastating diseases, e.g. cancer, type-II diabetes mellitus, Alzheimers’s dementia, cardiovascular and airway diseases (heart failure, cardiac arrhythmia, developmental defects, asthma and COPD), and infection diseases are associated with defective or derailed signaling processes, and research into the control of these processes clearly is of great public and social importance as well. My research group integrates in vivo, ex vivo translational pharmacology, molecular (cell) biology. Novel techniques like microfluidics, precision cut tissue slices and others.

Dr Anh Nguyen is an ARC DECRA Research Fellow and Head of the GPCR EcoPharmacology Lab at the Monash Institute of Pharmaceutical Sciences, where she leads an interdisciplinary program at the nexus of drug discovery and environmental toxicology. Her research focuses on how G protein-coupled receptors (GPCRs), critical regulators of cardiovascular and brain function, are disrupted by environmental pollutants. She investigates how microplastics, nanoplastics, and plastic-derived chemicals (e.g. BPA, phthalates) act as unregulated GPCR ligands, perturbing signalling pathways and contributing to cardiovascular and neurodegenerative diseases. By combining molecular pharmacology, computational modelling, and artificial intelligence, Dr Nguyen has developed an integrated discovery platform that advances both precision therapeutics and mechanistic environmental health science.

Dr Jake Martin is an ecologist and ecotoxicologist whose research explores how human-driven environmental change affects wildlife. He uses a combination of laboratory experiments, fieldwork, and meta-analysis to investigate the impacts of emerging chemical pollutants in aquatic ecosystems, with a particular focus on how pharmaceuticals influence animal behaviour. After completing his PhD and first postdoctoral role at Monash University, Jake moved to Sweden as a Formas Mobility Fellow, holding a joint position at the Swedish University of Agricultural Sciences (SLU) and Stockholm University. He is now an Alfred Deakin Research Fellow at Deakin University, where his research focuses on animal–microbe symbioses and the spatial and temporal dynamics of contaminant exposure.